Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 29, 1999 - Issue 10
91
Views
25
CrossRef citations to date
0
Altmetric
Research Article

Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4

, &
Pages 973-986 | Published online: 22 Sep 2008

References

  • ANDERSSON, T., MINERS, J. O., VERONESE, M. E. and B1RKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. British Journal of Clinical Pharmacology, 38, 131–137.
  • CANO, J. P., 1983, Clinical pharmacokinetics of benzodiazepines. In M. Tiengo and M. J. Cousins (eds), Pharmacological Basis of Anesthesiology, 3rd edn (New York: Raven), pp. 44–55.
  • CHAURET, N., GAUTHIER, A. and NicoLL -GRIFFITH, D. A., 1998, Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metabolism and Disposition, 26, 1–4.
  • COLTER, J. K., SomoGY1, A. A. and BOCHNER, F., 1997, Association between CYP2C19 genotype and proguanil oxidative polymorphism. British Journal of Clinical Pharmacology, 43, 659–660.
  • COLTER, J. K., SOMOGYI, A. A. and BOCHNER, F., 1998, Quantification of flunitrazepam's oxidative metabolites, 3-hydroxyflunitrazepam and desmethylflunitrazepam, in hepatic microsomal incubations by high-performance liquid chromatography. Journal of Chromatography B, 719, 87–92.
  • EAGLING, V. A., TIJA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
  • GRAHNEN, A., WENNERLUND, P., DAHLSTROM, B. and ECKERNAS, S.-A., 1991, Inter- and intra-individual variability in the concentration—effect (sedation) relationship of flunitrazepam. British Journal of Clinical Pharmacology, 31, 89–92.
  • HEIM, M. and MEYER, U. A., 1990, Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet, 336, 529–32.
  • HICKMAN, D., WANG, J.-P. and UNADKAT J. D., 1998, Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metabolism and Disposition, 26, 207–215.
  • LOWRY, O. H., ROSEBURG, N. J., FAR, A. L. and RANDALL, R. J., 1951, Measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
  • LUURILA, H., OLKKOLA, K. T. and NEUVONEN, P. J., 1996, Interaction between Erythromycin and the benzodiazepines diazepam and flunitrazepam. Pharmacology and Toxicology, 78, 117–122.
  • MATTILA, M. A. K. and LARNI, H. M., 1980, Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs, 20, 353–374.
  • MRAZ, J., JHEETA, P., GESCHER, A., HYLAND, R., THUMMEL, K. and THREADGILL, M. D., 1993, Investigation of the mechanistic basis of N,N-dimethylformamide toxicity. Metabolism of N,N-dimethylformamide and its deuterated isotopomers by cytochrome P450 2E1. Chemical Research in Toxicology, 6, 197–207.
  • NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
  • OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes, II. Solubilisation, purification and properties. Journal of Biological Chemistry, 234, 2374–2385.
  • SAN, L., TATO, J., TORRENS, M., CASTILLO, C., FAR, M. and CAW, J., 1993, Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug and Alcohol Dependence, 32, 281–286.
  • SCHWAB, G. E., RAUCY, J. L. and JoHNsoN, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroidhydroxylations by a-napthoflavone. Molecular Pharmacology, 33, 493–499.
  • TASSANEEYAKUL W., MAHAMED Z., BIRKETT, D. J., McMANus, M. E., VERONESE, M. E., TUKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J. 0., 1992, Caffeine as a probe for human cyto chromes P450: validation using cDNA expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetks, 2, 173–183.
  • UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
  • ZANGER, U. M., VI:L.13os, F., HARDWICK, J. P. and MEYER, U. A., 1988, Absence of hepatic cytochrome P450bufl causes genetically deficient debris oquine oxidation in man. Biochemistry, 27,5447–5454.
  • ZHANG, X.-J. and THOMAS, P. E., 1996, Erythromycin as a specific substrate for cytochrome P4503A isozymes and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metabolism and Disposition, 24, 23–27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.